AMGN
Amgen$265.51
AMGN info-0.66%ย โ€ข 24 H
Dividend Yield:2.9%
Global Rank#86
Market Cap$142.84B
YTD Performance-7.58%
P/E21.92
Revenue$26.32B
Change 7d-0.91%
SP500 BenchmarkUnderperform
P/S5.43
Earnings$6.55B

Amgen (AMGN) Stock Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behรงet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AMGN Stock Information

SymbolAMGN
Address
One Amgen Center DriveThousand Oaks, CA 91320-1799United States
Founded-
Trading hours9:30 AM - 4:00 PM ET
Websitehttps://www.amgen.com
Country๐Ÿ‡บ๐Ÿ‡ธ United States
Phone Number805 447 1000

Amgen (AMGN) Price Chart

-
Value:-

Amgen Overview: Key Details and Summary

Stock data
2022
Change
Price
$265.51
N/A
Market Cap
$142.84B
N/A
Shares Outstanding
538.00M
-5.61%
Employees
25.20K
N/A
Shareholder Equity
3.66B
-45.36%
Valuation
2022
Change
P/E Ratio
21.92
N/A
P/S Ratio
5.43
N/A
P/B Ratio
39.02
N/A
P/FCF
16.26
N/A
POE
0.00
N/A
Dividends
2022
Change
Dividend Yield
2.94%
N/A
Dividend per share
7.7993
N/A
Dividend Payout Ratio
0.6404
N/A
Growth
2022
Change
ROIC
0.1634
N/A
CAPEX
-936.00M
N/A
Return on Equity
1.7897
N/A
Earnings
2022
Change
Revenue
$26.32B
N/A
Earnings
$6.55B
N/A
Free Cash Flow
$8.79B
N/A
EPS
12.11
N/A
Earnings Yield
0.0456
N/A
Gross Margin
0.7566
N/A
Operating Margin
0.3634
N/A
Net income margin
0.2489
N/A
FCF Margin
0.3337
N/A
Financial Strength
2022
Change
Total Assets
$65.12B
N/A
Total Debt
$38.95B
N/A
Cash on Hand
$9.30B
N/A
Debt to Equity
$16.79
106.51%
Cash to Debt
0.2389
-0.98%
POE
0.0000
N/A
Current Ratio
$1.41
-11.11%
Other data
2022
Change
Buyback Yield
0.0445
N/A
ยฉ 2024 TopStocks.org
Facebook Icon
Twitter Icon
Linkedin Icon